Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

2.1K
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
2.1K
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants01:18

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants

2.5K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
2.5K
Venous Thrombosis III: Interprofessional Care01:29

Venous Thrombosis III: Interprofessional Care

395
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
395
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

1.4K
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
1.4K
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists01:23

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

545
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
545
Therapeutic Index01:13

Therapeutic Index

7.1K
The therapeutic index of a drug is a key parameter in pharmacology that quantifies the relative safety of a drug by calculating the ratio between the dose that causes toxicity in half the population (50%) to the dose that proves to be effective for half the population (50%). It provides a spectrum of doses for a particular drug ranging from effective to potentially toxic. To illustrate, consider an anticoagulant agent like warfarin. It possesses a narrow window within its therapeutic index to...
7.1K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Synthesis of a C-2 Functionalized l-Iduronic Acid Derivative as a Candidate Pharmacological Chaperone for MPS II (Hunter Syndrome).

Chemistry, an Asian journal·2026
Same author

Keratinocyte self-renewal and differentiation is dictated by extrinsic signals from dermal extracellular matrices.

Open biology·2025
Same author

An Automated Radiosynthesis of [68Ga]Ga-FAPI-46 for Routine Clinical Use.

Journal of visualized experiments : JoVE·2024
Same author

Automated radiosynthesis of [<sup>89</sup>Zr]Zr-DFOSq-Durvalumab for imaging of PD-L1 expressing tumours in vivo.

Nuclear medicine and biology·2023
Same author

Development of a high-performance liquid chromatography method for rapid radiochemical purity measurement of [<sup>18</sup> F]PSMA-1007, a PET radiopharmaceutical for detection of prostate cancer.

Journal of labelled compounds & radiopharmaceuticals·2023
Same author

Fabrication and Evaluation of Electrospun Silk Fibroin/Halloysite Nanotube Biomaterials for Soft Tissue Regeneration.

Polymers·2022

Related Experiment Video

Updated: Feb 21, 2026

Using a GFP-tagged TMEM184A Construct for Confirmation of Heparin Receptor Identity
10:41

Using a GFP-tagged TMEM184A Construct for Confirmation of Heparin Receptor Identity

Published on: February 17, 2017

8.5K

Heparin Mimetics: Their Therapeutic Potential.

Shifaza Mohamed1,2, Deirdre R Coombe3

  • 1School of Biomedical Sciences, Curtin Health Innovation Research Institute, Faculty of Health Sciences, Curtin University, Perth 6102, Western Australia. Shifaza.Mohamed@curtin.edu.au.

Pharmaceuticals (Basel, Switzerland)
|October 5, 2017
PubMed
Summary

Heparin mimetics, highly sulfated compounds, show promise beyond anticoagulation. Research highlights their potential in cancer therapy by inhibiting tumor spread and angiogenesis, and in treating inflammatory diseases.

Keywords:
anti-inflammatoryanticoagulantcancerglycosaminoglycanheparan sulfateheparinheparin mimetics

More Related Videos

Rapid Point-of-Care Assay of Enoxaparin Anticoagulant Efficacy in Whole Blood
11:17

Rapid Point-of-Care Assay of Enoxaparin Anticoagulant Efficacy in Whole Blood

Published on: October 12, 2012

14.4K
Author Spotlight: Developing Parmodulins to Target Protease-Activated Receptors for Inflammation Control
07:13

Author Spotlight: Developing Parmodulins to Target Protease-Activated Receptors for Inflammation Control

Published on: May 24, 2024

1.0K

Related Experiment Videos

Last Updated: Feb 21, 2026

Using a GFP-tagged TMEM184A Construct for Confirmation of Heparin Receptor Identity
10:41

Using a GFP-tagged TMEM184A Construct for Confirmation of Heparin Receptor Identity

Published on: February 17, 2017

8.5K
Rapid Point-of-Care Assay of Enoxaparin Anticoagulant Efficacy in Whole Blood
11:17

Rapid Point-of-Care Assay of Enoxaparin Anticoagulant Efficacy in Whole Blood

Published on: October 12, 2012

14.4K
Author Spotlight: Developing Parmodulins to Target Protease-Activated Receptors for Inflammation Control
07:13

Author Spotlight: Developing Parmodulins to Target Protease-Activated Receptors for Inflammation Control

Published on: May 24, 2024

1.0K

Area of Science:

  • Medicinal Chemistry
  • Biochemistry
  • Pharmacology

Background:

  • Heparin mimetics are synthetic glycosaminoglycan analogues designed for enhanced therapeutic properties.
  • Current research explores their potential beyond anticoagulation, focusing on anticancer and anti-inflammatory applications.

Purpose of the Study:

  • To review the therapeutic potential of heparin mimetics in oncology and inflammatory diseases.
  • To highlight the non-anticoagulant activities and novel applications of these compounds.

Main Methods:

  • Literature review of heparin mimetics' mechanisms of action.
  • Analysis of preclinical and clinical data for anticancer and anti-inflammatory effects.

Main Results:

  • Heparin mimetics inhibit heparanase and angiogenesis, showing potential as anti-cancer agents (e.g., PI-88 in clinical trials).
  • These compounds modulate inflammatory pathways by interacting with complement proteins, selectins, and chemokines, demonstrating efficacy in animal models.

Conclusions:

  • Heparin mimetics offer promising therapeutic strategies for cancer and inflammatory diseases, leveraging their non-anticoagulant activities.
  • Further development of low/non-anticoagulant heparin mimetics could lead to a new class of treatments.